The effect of 1.25 dihydroxy vitamin D on IMT, iron indicators changes induced by inflammation and inflammatory biomarkers in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201211106415N3

Enrollment

Registered

2013-03-10

Start date

2013-04-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease. Chronic kidney disease

Interventions

It is clinical trial without placebo control of 40 subjects between the ages of 45 and 75 years with chronic kidney disease. CKD patients will be confirmed (by physician) at the initial of diagnosis.

Treatment - Drugs

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria:patients with chronic kidney disease; Patient's written consent to participate in the study; CKD patients with hypovitaminosis D (serum level of 25hydroxy vitamin D<30ng/ml); Not taking ferrous sulfate or Intravenous iron therapy; no evidence of iron deficiencyanemia Exclusion Crieteria: -

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
IMT. Timepoint: Before intervention and after intervention (2month of intervention). Method of measurement: Sonography.;Hepcidin. Timepoint: before intervention and after intervention (2month of intervention). Method of measurement: Measuring serum concentration (ng/ml).;Serum 25 hydroxy vitamin D concentration. Timepoint: Before intervention and after intervention (2month of intervention). Method of measurement: Measuring serum concentration (ng/ml).	—

Measure

Time frame

IMT. Timepoint: Before intervention and after intervention (2month of intervention). Method of measurement: Sonography.;Hepcidin. Timepoint: before intervention and after intervention (2month of intervention). Method of measurement: Measuring serum concentration (ng/ml).;Serum 25 hydroxy vitamin D concentration. Timepoint: Before intervention and after intervention (2month of intervention). Method of measurement: Measuring serum concentration (ng/ml).

—

Secondary

Measure	Time frame
TIBC. Timepoint: Before and after intervention(2 month). Method of measurement: Serum concentration (micro/dl).;Serum iron. Timepoint: Before and after intervention(2 month). Method of measurement: Serum iron concentration (microgr/dl).;Ferritin. Timepoint: Before and after intervention(2 month). Method of measurement: Serum ferritin concentration (ng/ml).;IL6. Timepoint: Before and after intervention(2 month). Method of measurement: Serum IL6 concentration (pg/ml).;Hemoglobin. Timepoint: Before and after intervention(2 month). Method of measurement: Blood hemoglobin concentration (mg/dl).;Homocystein. Timepoint: Before and after intervention(2 month). Method of measurement: Serum homocystein concentration (micromol/l).;Serum PTH. Timepoint: Before and after intervention(2 month). Method of measurement: Serum PTH concenteration (pg/ml).;Serum calcium. Timepoint: Before and after intervention(2 month). Method of measurement: Serum calcium concentration (mg/dl).;Serum phosphorus. Timepoint: Before and after intervention(2 month). Method of measurement: Serum phosphorus concentration (mg/dl).	—

Measure

Time frame

TIBC. Timepoint: Before and after intervention(2 month). Method of measurement: Serum concentration (micro/dl).;Serum iron. Timepoint: Before and after intervention(2 month). Method of measurement: Serum iron concentration (microgr/dl).;Ferritin. Timepoint: Before and after intervention(2 month). Method of measurement: Serum ferritin concentration (ng/ml).;IL6. Timepoint: Before and after intervention(2 month). Method of measurement: Serum IL6 concentration (pg/ml).;Hemoglobin. Timepoint: Before and after intervention(2 month). Method of measurement: Blood hemoglobin concentration (mg/dl).;Homocystein. Timepoint: Before and after intervention(2 month). Method of measurement: Serum homocystein concentration (micromol/l).;Serum PTH. Timepoint: Before and after intervention(2 month). Method of measurement: Serum PTH concenteration (pg/ml).;Serum calcium. Timepoint: Before and after intervention(2 month). Method of measurement: Serum calcium concentration (mg/dl).;Serum phosphorus. Timepoint: Before and after intervention(2 month). Method of measurement: Serum phosphorus concentration (mg/dl).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKatayoun Kadkhodazadeh

Faculty of Health, Tehran University of Medical Sciences

kattyka63@yahoo.com+98 21 4293 3031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026